Filtered By:
Cancer: Prostate Cancer

This page shows you your search results in order of date. This is page number 10.

Order by Relevance | Date

Total 543 results found since Jan 2013.

Blood Test for Early Stage Cancer Diagnosis: Interview with Dr. Van Etten, CMO of Laboratory for Advanced Medicine
The Laboratory for Advanced Medicine (LAM), a biotechnology company headquartered in the US, offers non-invasive, early stage cancer detection tests that will use the IvyGene Platform. These IvyGene tests are based on detecting genomic DNA shed by ca...
Source: Medgadget - March 4, 2019 Category: Medical Devices Authors: Conn Hastings Tags: Diagnostics Exclusive Oncology Pathology Source Type: blogs

Your Risk Of Prostate Cancer Just Dropped Precipitously. Here ’s Why
Most men diagnosed with prostate cancer don’t die of the disease. Between 2011 and 2015, 112.6 per 100,000 men per year were diagnosed with prostate cancer in the U.S., but only 19.5 per 100,000 men per year died of the disease … Continue reading → The post Your Risk Of Prostate Cancer Just Dropped Precipitously. Here’s Why appeared first on PeterUbel.com.
Source: blog.bioethics.net - March 1, 2019 Category: Medical Ethics Authors: PeterUbel.com Tags: Health Care Behavioral Economics and Public Policy health policy Medical Decision Making Peter Ubel syndicated Source Type: blogs

Diet and exercise limit heart disease risk in men undergoing hormonal treatments for advanced prostate cancer
Men with advanced prostate cancer are typically treated with drugs that prevent the body from making or using testosterone. A hormone (or an androgen, as it’s known), testosterone drives prostate cancer cells to grow faster, so shutting it down is essential to keeping the illness in check. About 600,000 men with advanced prostate cancer in the United States today are undergoing this type of anti-hormonal treatment, which is called androgen deprivation therapy (ADT). But even as ADT helps men live longer, it exerts a toll on the body. Men can lose muscle and bone mass, gain weight, and they face higher risks for heart dis...
Source: Harvard Health Blog - February 25, 2019 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Living With Prostate Cancer Prostate Knowledge Treatments HPK Source Type: blogs

Preserving fertility during cancer treatments
Cancer treatment — and cancer itself — can threaten fertility. This is a tremendously important survivorship issue for many people. As an oncologist, I’m often asked questions about preserving fertility during cancer treatment. If this issue affects you, here is an overview of key options. When should you talk to your cancer team about fertility? Future children may not be foremost on your mind when you are diagnosed with cancer. Soon afterward, though, it’s worth talking to your doctor about fertility issues, if this is important to you now or might one day become important. Your doctor can explain: the risk that...
Source: Harvard Health Blog - February 4, 2019 Category: Consumer Health News Authors: Ann Partridge, MD, MPH Tags: Cancer Fertility Infertility Source Type: blogs

A story of treatment failure and end-of-life decisions
Part 4 of a  series. By the time my father’s metastatic prostate cancer was diagnosed, he was already experiencing symptoms of poor appetite and weight loss, which grew progressively worse following his first hospital admission. As his nutritional status continued to decline, the protein level in his blood d ecreased, causing significant fluid buildup in his legs […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.
Source: Kevin, M.D. - Medical Weblog - January 30, 2019 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/blog/post-author/iris-kulbatski" rel="tag" > Iris Kulbatski, PhD < /a > < /span > Tags: Conditions Critical Care Oncology/Hematology Source Type: blogs

Hormonal therapy for aggressive prostate cancer: How long is enough?
This study reaffirms what many clinicians have put into practice: longer duration hormonal therapy in appropriately selected patient populations provides a greater benefit,” said Dr. Marc Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center, and editor in chief of HarvardProstateKnowledge.org. “Prior studies using three years of hormonal therapy have also shown this, but it is important to recognize that some men may have significantly delayed return of the body’s testosterone upon completion of the therapy — a fact that needs to be discussed when con...
Source: Harvard Health Blog - January 28, 2019 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Living With Prostate Cancer Prostate Knowledge Treatments HPK Source Type: blogs

Fight Aging! Newsletter, January 28th 2019
In this study, we show that calorie restriction is protective against age-related increases in senescence and microglia activation and pro-inflammatory cytokine expression in an animal model of aging. Further, these protective effects mitigated age-related decline in neuroblast and neuronal production, and enhanced olfactory memory performance, a behavioral index of neurogenesis in the SVZ. Our results support the concept that calorie restriction might be an effective anti-aging intervention in the context of healthy brain aging. Greater Modest Activity in Late Life Correlates with Lower Incidence of Dementia ...
Source: Fight Aging! - January 27, 2019 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Past Progress Towards Control of Cancer Has Been Slow, Steady, and Incremental
Mortality rates for cancer have diminished slowly and steadily over the past few decades. This is a matter of prevention on the one hand and improvements in early detection of cancer on the other. When caught early enough, even comparatively crude approaches to therapy have a decent chance of controlling and eliminating the cancer. This trend will no doubt continue, but the more rapid, more effective progress that we'd like to see will only emerge given the advent of universal cancer therapies, those that strike at mechanisms, such as telomere lengthening, that are shared by many or all cancers. That is a plausible goal fo...
Source: Fight Aging! - January 23, 2019 Category: Research Authors: Reason Tags: Daily News Source Type: blogs

Dad's Decision Not To Be Treated for Cancer Upsets Daughter
Photo credit Matteo Vistocco Dear Carol: There’s probably no right answer to what I’m asking but I felt the need to write, just for comfort. My mother died when I was in my teens so Dad has been the only parent that I’ve had for more than 20 years. I have no siblings. Dad’s now in his seventies and has been diagnosed with prostate cancer. He’s beaten both melanoma and lung cancer in the past, but he tells me that this cancer should be slow growing and that he’ll probably die before it’s a problem so he doesn’t want to treat it. I want him to go full-on with every treatment possible. I watc...
Source: Minding Our Elders - January 13, 2019 Category: Geriatrics Authors: Carol Bradley Bursack Source Type: blogs

A story of missed opportunities and medical missteps
Part 2 of a  series. My own self-appointed role as my father’s health care advocate during his prostate cancer battle was a natural consequence of my training as a medical researcher. After earning a PhD in medical science, I became the elected family health and wellness guru, offering insight into everythin g from hangnails to stem cells, […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.
Source: Kevin, M.D. - Medical Weblog - January 9, 2019 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/blog/post-author/iris-kulbatski" rel="tag" > Iris Kulbatski, PhD < /a > < /span > Tags: Conditions Oncology/Hematology Urology Source Type: blogs

Long-term statin use protects against prostate cancer death
Statins and other drugs that lessen cardiovascular disease risk by lowering blood lipids rank among the world’s most prescribed medications. And for the men who take them, accumulating evidence has for years pointed to another added benefit: a lower risk of developing prostate cancer. Now researchers are reporting that long-term statin use (more than 10 years) can also reduce the odds of a prostate cancer death. The new findings come from a study led by Alison Mondul, a cancer epidemiologist at the University of Michigan School of Public Health. Mondul says that most men develop slow-growing, indolent prostate cancers th...
Source: Harvard Health Blog - January 7, 2019 Category: Consumer Health News Authors: Charlie Schmidt Tags: Living With Prostate Cancer Prostate Knowledge HPK Source Type: blogs

Last Month in Oncology with Dr. Bishal Gyawali
By BISHAL GYAWALI MD  Long list of news in lung cancer September was an important month in oncology—especially for lung cancer. The World Conference in Lung Cancer (WCLC) 2018 gave us some important practice-changing results, also leading to four NEJM publications. The trial with most public health impact is unfortunately not published yet. It’s the NELSON trial that randomised more than 15000 asymptomatic people at high risk of lung cancer to either CT-based screening for lung cancer or to no screening and found a significant reduction in lung cancer mortality rates among the screened cohort compared with the contr...
Source: The Health Care Blog - January 4, 2019 Category: Consumer Health News Authors: matthew holt Tags: Research Bishal Gyawali Breast cancer Cancer drugs Clinical Trials health spending immunotherapy Lung cancer Oncology pembrolizumab Source Type: blogs

The Death of Cancer: Book Review and Reflections
By CHADI NABHAN MD, MBA, FACP Some books draw you in based on a catchy title, a provocative book jacket, or familiarity with the author. For me, recollections of medical school primers written by the renowned lymphoma pioneer Vincent DeVita Jr. and my own path as an oncologist immediately attracted me to “The Death of Cancer.” I felt a connection to this book before even reading it and prepped myself for an optimistic message about how the cancer field is moving forward. Did I get what I bargained for? Co-authored with his daughter, Elizabeth DeVita-Raeburn, DeVita brings us back decades ago to when he had just st...
Source: The Health Care Blog - January 1, 2019 Category: Consumer Health News Authors: matthew holt Tags: Health Care Books Physicians Book Review Chadi Nabhan Chemotherapy Oncology randomized controlled trials The Death of Cancer Vincent DeVita Source Type: blogs

Diagnosed with prostate cancer? You must ask these 10 questions.
Prostate cancer often presents unique challenges to patients and physicians alike. It can be indolent and non-aggressive — or life-threatening and everything in between. Unlike most cancers that have a dedicated roadmap for treatment for prostate cancer revolves around opinions and biases. To help patients navigate the landmine of prostate cancer, I’ve compiled a list […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.
Source: Kevin, M.D. - Medical Weblog - December 20, 2018 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/blog/post-author/naeem-rahman" rel="tag" > Naeem Rahman, MD < /a > < /span > Tags: Conditions Oncology/Hematology Urology Source Type: blogs

Last Month in Oncology with Dr. Bishal Gyawali: November 2018
By BISHAL GYAWALI MD  Keynote speech There was a very sobering piece in NEJM by the FDA last month in which the authors try to explore what went wrong with the Keynote-183, Keynote-185 and checkmate 602 trials testing PD-1 inhibitors combinations with pomalidomide or lenalidomide and dexamethasone in multiple myeloma. Interim analysis of Keynote 183 and 185 revealed detrimental effects on overall survival (OS) with hazard ratios of 1.61 and 2.06, not explained by differences in toxicities alone. The checkmate 602 trial was also halted in light of these findings and also showed higher mortality in the nivolumab combina...
Source: The Health Care Blog - December 17, 2018 Category: Consumer Health News Authors: matthew holt Tags: Pharmaceuticals Physicians Bishal Gyawali Cancer drugs cancer immunotherapy Clinical Trials FDA Oncology PD-1 inhibitors Source Type: blogs